本文印刷
全画面プリント
数理人口学・数理生物学セミナー
過去の記録 ～04/18｜次回の予定｜今後の予定 04/19～
2016年10月28日(金)
13:30-14:30 数理科学研究科棟(駒場) 126号室
原 朱音 氏 (九州大学システム生命科学府)
When is the allergen immunotherapy effective? (JAPANESE)
原 朱音 氏 (九州大学システム生命科学府)
When is the allergen immunotherapy effective? (JAPANESE)
[ 講演概要 ]
Allergen immunotherapy is a method to treat allergic symptoms, for example rhinitis and sneezing in Japanese cedar pollen allergy (JCPA). In the immunotherapy of JCPA, patients take in a small amount of pollen over several years, which suppress severe allergic symptoms when exposed to a large amount of environmental pollen after the therapy. We develop a simple mathematical model to identify the condition for successful therapy. We consider the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg) and both of them are differentiated from naive T cells. We assume that Treg cells have a much longer lifespan than Th2 cells, which makes Treg cells accumulate over many years during the therapy.
We regard that the therapy is successful if (1) without therapy the patient develops allergic symptoms upon exposure to the environmental pollen, (2) the patient does not develop allergic symptoms caused by the therapy itself, and (3) with therapy the patient does not develop symptoms upon exposure. We find the conditions of each parameter for successful therapy. We also find that the therapy of linearly increasing dose is able to reduce the risk of allergic symptoms caused by the therapy itself, rather than constant dose. We would like to consider application of this model to other kind of allergy, such as food allergy.
Allergen immunotherapy is a method to treat allergic symptoms, for example rhinitis and sneezing in Japanese cedar pollen allergy (JCPA). In the immunotherapy of JCPA, patients take in a small amount of pollen over several years, which suppress severe allergic symptoms when exposed to a large amount of environmental pollen after the therapy. We develop a simple mathematical model to identify the condition for successful therapy. We consider the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg) and both of them are differentiated from naive T cells. We assume that Treg cells have a much longer lifespan than Th2 cells, which makes Treg cells accumulate over many years during the therapy.
We regard that the therapy is successful if (1) without therapy the patient develops allergic symptoms upon exposure to the environmental pollen, (2) the patient does not develop allergic symptoms caused by the therapy itself, and (3) with therapy the patient does not develop symptoms upon exposure. We find the conditions of each parameter for successful therapy. We also find that the therapy of linearly increasing dose is able to reduce the risk of allergic symptoms caused by the therapy itself, rather than constant dose. We would like to consider application of this model to other kind of allergy, such as food allergy.
